Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weili He

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Clinical Trials (London, England)|January 21, 2006
Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal womenWeili He, Weiping Deng
Therapeutic Innovation & Regulatory Science|May 23, 2026
Arbitrated Indirect Treatment ComparisonsYixin Fang, Weili He
Clinical Trials (London, England)|March 7, 2022
Practical considerations in utilizing cluster randomized controlled trials conducted in biopharmaceutical industryYixin Fang, Weili He
Clinical Trials (London, England)|November 11, 2005
Use of joint models to assess treatment effects on disease markers and clinical events: the Proscar Long-Term Efficacy and Safety Study (PLESS)Weili He, Weichung Joe Shih
Therapeutic Innovation & Regulatory Science|June 20, 2020
A Statistical Roadmap for Journey from Real-World Data to Real-World EvidenceYixin Fang, Hongwei Wang, Weili He
Statistics in Medicine|December 14, 2011
A framework for joint modeling and joint assessment of efficacy and safety endpoints for probability of success evaluation and optimal dose selectionWeili He, Xiting Cao, Lu Xu
Statistics in Medicine|July 19, 2005
A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trialsWeili He, Jun Liu, Bruce Binkowitz, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
On a Stepwise Quantitative Approach for Benefit-Risk AssessmentWeili He, Yaxuan Sun, Qing Li, et al.
Contemporary Clinical Trials|July 28, 2020
Key considerations in the design of real-world studiesYixin Fang, Weili He, Hongwei Wang, et al.
Contemporary Clinical Trials|July 6, 2020
A new framework to address challenges in quantitative benefit-risk assessment for medical productsBo Fu, Xuefeng Li, John Scott, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Clinical Trials (London, England)|January 21, 2006
Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal womenWeili He, Weiping Deng
Therapeutic Innovation & Regulatory Science|May 23, 2026
Arbitrated Indirect Treatment ComparisonsYixin Fang, Weili He
Clinical Trials (London, England)|March 7, 2022
Practical considerations in utilizing cluster randomized controlled trials conducted in biopharmaceutical industryYixin Fang, Weili He
Clinical Trials (London, England)|November 11, 2005
Use of joint models to assess treatment effects on disease markers and clinical events: the Proscar Long-Term Efficacy and Safety Study (PLESS)Weili He, Weichung Joe Shih
Therapeutic Innovation & Regulatory Science|June 20, 2020
A Statistical Roadmap for Journey from Real-World Data to Real-World EvidenceYixin Fang, Hongwei Wang, Weili He
Statistics in Medicine|December 14, 2011
A framework for joint modeling and joint assessment of efficacy and safety endpoints for probability of success evaluation and optimal dose selectionWeili He, Xiting Cao, Lu Xu
Statistics in Medicine|July 19, 2005
A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trialsWeili He, Jun Liu, Bruce Binkowitz, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
On a Stepwise Quantitative Approach for Benefit-Risk AssessmentWeili He, Yaxuan Sun, Qing Li, et al.
Contemporary Clinical Trials|July 28, 2020
Key considerations in the design of real-world studiesYixin Fang, Weili He, Hongwei Wang, et al.
Contemporary Clinical Trials|July 6, 2020
A new framework to address challenges in quantitative benefit-risk assessment for medical productsBo Fu, Xuefeng Li, John Scott, et al.
Pageof 4